Human stem cells engineered to seek out and kill HIV

In a major breakthrough in the fight against AIDS, scientists claim to have for the first time shown that human stem cells can be genetically engineered to seek out and kill HIV-infected cells in a living organism.

The study demonstrates f

or the first time that engineering stem cells to form immune cells that target HIV is effective in suppressing the virus in living tissues in an animal model, said lead scientist Scott G Kitchen.

He added: “We believe that this study lays the groundwork for the potential use of this type of an approach in combating HIV infection in infected individuals, in hopes of eradicating the virus from the body.”

In their previous research, the scientists took CD8 cytotoxic T lymphocytes — the “killer” T cells that help fight infection — from an HIV-infected individual and identified the molecule known as the T cell receptor, which guides T cell in recognising and killing HIV-infected cells.

In their latest research, the scientists at California University similarly engineered human blood stem cells and found that they can form mature T cells that can attack HIV in tissues where the virus resides and replicates.

They did so by using a surrogate model, the humanised mouse, in which HIV infection closely resembles the disease and its progression in humans.

In a series of tests on the mice’s peripheral blood, plasma and organs conducted two weeks and six weeks after introducing the engineered cells, the scientists found that the number of CD4 “helper” T cells — which become depleted as a result of HIV infection — increased, while levels of HIV in the blood decreased.

CD4 cells are white blood cells that are an important component of immune system, helping to fight off infections.

These results indicated that the engineered cells were capable of developing and migrating to the organs to fight infection there, the PLoS Pathogens journal reported.

“We believe that this is the first step in developing a more aggressive approach in correcting the defects in the human T cell responses that allow HIV to persist in infected people,” Mr. Kitchen said.

Keywords: HIV-AIDS, stem cells research

How dangerous food-borne pathogen evades body”s defenses

Washington, May 14 (ANI): Stanford University School of Medicine investigators have deciphered how Listeria monocytogenes, a dangerous food-borne pathogen, slips through the intestine”s defenses and causes disease.

This bacterial strain thrives in salty or cold environments where prissier pests might perish: cold cuts, smoked salmon, soft cheeses and many a refrigerator. Abundant in the environment, it seldom causes disease in humans — but when it does, it”s deadly.

Manuel Amieva, MD, PhD, assistant professor of pediatrics and of microbiology and immunology, is the senior author of a study that describes the way Listeria grabs onto molecular handles on cells in the small intestine and then switches on those cells” own uptake systems to hitch a ride inside.

The study will be published online May 13 in PLoS Pathogens. Mickey Pentecost, PhD, a recent graduate from Amieva”s laboratory, is the first author.

We think of the small intestine as a long, smooth, hollow tube through which torrents of nutrient-rich food flow. But close inspection shows that the gut”s inner surface lining, known as the intestinal epithelium, is anything but smooth. In fact, it”s much more like the Rocky Mountains than the Great Plains. The gut”s serrated character vastly increases its surface area, which in turn increases nutrient absorption.

The microscopic mountains of the intestine”s rugged surface terrain are called villi. Amieva and his colleagues have previously shown that cells at the very tips of villi are particularly vulnerable to infection by Listeria. But gaining that unauthorized access is no mean feat. The cells of the intestinal epithelium are tightly stitched together by molecules on their cell surfaces that connect them to each other.

The tight junctions formed in this way effectively seal off the intestine from the microbes that course through our digestive tracts. And luckily so: Even normally benign bugs — there are trillions of them in our gut — would cause serious problems if they could squeeze through the intestinal wall and enter the bloodstream.

Listeria and other invasive organisms manage to get around that seal, said Amieva. “You get a new intestinal epithelial lining every week,” he said. “The cells at the tips of the villi are constantly dying and being shed, at the rate of 10 billion a day. When a cell dies it is shed into the hollow space of the gut. To avoid leaving holes, the surrounding cells quickly move closer together and re-assemble tight junctions. But in the process, the normally hidden molecules that dot the sides of the cells abutting the hole — like the sides of teeth adjacent to one that just fell out — get transiently exposed.”

Listeria exploits these exposed spots by doing a sophisticated two-step.

Like many other microbes, Listeria manufactures a couple of hooks (Listeria”s are known as Internalin A and Internalin B) that grab onto specific molecules protruding from cells of the intestinal lining. Internalin A”s targeted molecule, E-cadherin, is a key player in forging the junctions between adjacent cells of the gut epithelium. The target for Internalin B is C-Met, a receptor for a growth factor (growth factors are external molecules that can drastically change a cell”s behavior).

Both E-cadherin and C-Met are typically located along the normally inaccessible sides of villus cells. This was puzzling, said Amieva. “E-cadherin and C-Met would seem to be unlikely attachment sites. Why on earth would a microbe pick such hard-to-reach sites to grab onto?” (ANI)

Common cold virus harnessed for use as cancer killer

London, May 22 (ANI): A common cold virus that wipes out cancer cells in mice – without harming healthy ones – has been developed by scientists.

They modified a common bug called on adenovirus, which typically causes chest infections, so that it delivered vital genetic therapy to tumours without poisoning the liver, reports The Scotsman.

The virus was allowed to keep enough of its genetic “signature” to trigger an immune response, which safely eradicated it after the job was done.

The work was reported in the journal PLoS Pathogens.

Lead author Professor Leonard Seymour, of Oxford University, said: “The approach we developed is easy to use and flexible.

“It may help in the development of future therapeutic viruses that are specific to certain disease sites.” (ANI)